Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Owing to its poly-anionic charge and large hydrodynamic volume, polysialic acid (polySia) attached to neural cell adhesion molecule regulates axon-axon and axon-substratum interactions and signalling, particularly, in the development of the central nervous system (CNS). Expression of polySia is spatiotemporally regulated by the action of two polysialyl transferases, namely ST8SiaII and ST8SiaIV. PolySia expression peaks during late embryonic and early post-natal period and maintained at a steady state in adulthood in neurogenic niche of the brain. Aberrant polySia expression is associated with neurological disorders and brain tumours. Investigations on the structure and functions, over the past four decades, have shed light on the physiology of polySia. This review focuses on the biological, biochemical, and chemical tools available for polySia engineering. Genetic knockouts, endo-neuraminidases that cleave polySia, antibodies, exogenous expression, and neuroblastoma cells have provided deep insights into the ability of polySia to guide migration of neuronal precursors in neonatal brain development, neuronal clustering, axonal pathway guidance, and axonal targeting. Advent of metabolic sialic acid engineering using ManNAc analogues has enabled reversible and dose-dependent modulation polySia in vitro and ex vivo. In vivo, ManNAc analogues readily engineer the sialoglycans in peripheral tissues, but show no effect in the brain. A recently developed carbohydrate-neuroactive hybrid strategy enables a non-invasive access to the brain in living animals across the blood-brain barrier. A combination of recent advances in CNS drugs and imaging with ManNAc analogues for polySia modulation would pave novel avenues for understanding intricacies of brain development and tackling the challenges of neurological disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1042/ETLS20180008DOI Listing

Publication Analysis

Top Keywords

mannac analogues
12
polysia
10
structure functions
8
polysia expression
8
neurological disorders
8
brain development
8
brain
6
chemical biological
4
biological methods
4
methods probing
4

Similar Publications

Metabolic Probing of Sialylated Glycoconjugates with Fluorine-Selenol Displacement Reaction (FSeDR).

ACS Bio Med Chem Au

February 2025

Department of Chemistry, Temple University, 1901 N. 13th Street, Philadelphia, Pennsylvania 19122, United States.

Dysregulated sialic acid biosynthesis is characteristic of the onset and progression of human diseases including hormone-sensitive prostate cancer and breast cancer. The sialylated glycoconjugates involved in this process are therefore important targets for identification and functional studies. To date, one of the most common strategies is metabolic glycoengineering, which utilizes -acetylmannosamine (ManNAc) analogues such as -azidoacetylmannosamine (ManNAz) to hijack sialic acid biosynthesis and label the sialylated glycoconjugates with "click chemistry (CuAAC)" tags.

View Article and Find Full Text PDF

Examining structure-activity relationships of ManNAc analogs used in the metabolic glycoengineering of human neural stem cells.

Biomater Adv

April 2025

Department of Biomedical Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD, USA; Translational Tissue Engineering Center, Whiting School of Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address:

This study defines biochemical mechanisms that contribute to novel neural-regenerative activities we recently demonstrated for thiol-modified ManNAc analogs in human neural stem cells (hNSCs) by comparing our lead drug candidate for brain repair, "TProp," to a "size-matched" N-alkyl control analog, "But." These analogs biosynthetically install non-natural sialic acids into cell surface glycans, altering cell surface receptor activity and adhesive properties of cells. In this study, TProp modulated sialic acid-related biology in hNSCs to promote neuronal differentiation through modulation of cell adhesion molecules (integrins α6, β1, E-cadherin, and PSGL-1) and stem cell markers.

View Article and Find Full Text PDF

A pilot trial for efficacy confirmation of 6'-sialyllactose supplementation in GNE myopathy: Randomized, placebo-controlled trial.

Mol Genet Metab

January 2025

Department of Neurology, Pusan National University School of Medicine, Busan, Republic of Korea; Department of Neurology and Biomedical Research institute, Pusan National University Yangsan Hospital, Gyeongsangnam-do, Republic of Korea. Electronic address:

Article Synopsis
  • GNE myopathy is a rare genetic muscle disorder that leads to weakness in the ankles and muscle degeneration, caused by mutations in the GNE gene that reduce sialic acid production.
  • A clinical trial tested a supplement, 6'-sialyllactose (6SL), at doses of 3g and 6g to see if it could improve muscle strength and health, revealing better outcomes in muscle strength and reduced degeneration with the higher dose.
  • The latest study involved 11 participants to compare 6SL with a placebo group over 48 weeks, finding no major differences in muscle strength but a significant degeneration in muscle fat measured by MRI, indicating muscle health issues, particularly in the placebo group.
View Article and Find Full Text PDF
Article Synopsis
  • - Understanding the S-layer anchoring in bacteria involves non-covalent interactions between S-layer domains and secondary cell wall polymers (SCWPs), with specific roles for ManNAc ligands and the MnaA enzyme in SCWP biosynthesis.
  • - Research focused on producing MnaA and its variants to analyze their kinetic properties, test allosteric activation by UDP-GlcNAc, and explore the effects of tunicamycin as a potential inhibitor using crystal structure analysis and molecular docking.
  • - The study revealed the crystal structure of MnaA and confirmed the conservation of key residues, finding that UDP-GlcNAc boosts reaction rates but isn't essential for its function, while tunicamycin doesn't
View Article and Find Full Text PDF

Sialyllactose supplementation enhances sialylation of Fc-fusion glycoprotein in recombinant Chinese hamster ovary cell culture.

J Biotechnol

September 2024

Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, South Korea; Department of Bioprocess Engineering, KRIBB School of Biotechnology, University of Science and Technology (UST), 217 Gajeong-ro, Yuseo

Sialylation during N-glycosylation plays an important role in the half-life of therapeutic glycoproteins in vivo and has sparked interest in the production of therapeutic proteins using recombinant Chinese hamster ovary (rCHO) cells. To improve the sialylation of therapeutic proteins, we examined the effect of sialyllactose supplementation on sialylation of Fc-fusion glycoproteins produced in rCHO cells. Two enzymatically-synthesized sialyllactoses, 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), were administered separately to two rCHO cell lines producing the same Fc-fusion glycoprotein derived from DUKX-B11 and DG44, respectively.

View Article and Find Full Text PDF